- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02272803
Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan
A Phase 2, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma in Japan
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Kasama-shi, Japan, 3091793
- Local Institution
-
-
Aichi
-
Nagoya-shi, Aichi, Japan, 4600001
- Local Institution
-
Nagoya-shi, Aichi, Japan, 4678602
- Local Institution
-
-
Aomori
-
Aomori-shi, Aomori, Japan, 0308553
- Local Institution
-
-
Chiba
-
Chiba-shi, Chiba, Japan, 2608677
- Local Institution
-
Kamogawa-shi, Chiba, Japan, 2968602
- Local Institution
-
-
Ehime
-
Matsuyama-shi, Ehime, Japan, 7900024
- Local Institution
-
-
Fukuoka
-
Fukuoka-shi, Fukuoka, Japan, 8128582
- Local Institution
-
-
Gunma
-
Maebashi-shi, Gunma, Japan, 3718511
- Local Institution
-
Shibukawa-shi, Gunma, Japan, 3770280
- Local Institution
-
-
Hiroshima
-
Fukuyama-shi, Hiroshima, Japan, 7200001
- Local Institution
-
-
Iwate
-
Morioka-shi, Iwate, Japan, 0208505
- Local Institution
-
-
Kagoshima
-
Kagoshima-shi, Kagoshima, Japan, 8920853
- Local Institution
-
-
Kyoto
-
Kyoto-shi, Kyoto, Japan, 6028566
- Local Institution
-
-
Miyagi
-
Sendai, Miyagi, Japan, 9808574
- Local Institution
-
-
Niigata
-
Niigata-shi, Niigata, Japan, 9518566
- Local Institution
-
-
Okayama
-
Okayama-shi, Okayama, Japan, 7011192
- Local Institution
-
-
Osaka
-
Osaka-shi, Osaka, Japan, 5438555
- Local Institution
-
Osaka-shi, Osaka, Japan, 5300012
- Local Institution
-
-
Saitama
-
Kawagoe-shi, Saitama, Japan, 3508550
- Local Institution
-
-
Shizuoka
-
Hamamatsu-shi, Shizuoka, Japan, 4313192
- Local Institution
-
-
Tochigi
-
Utsunomiya-shi, Tochigi, Japan, 3200834
- Local Institution
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 1138677
- Local Institution
-
Koto-ku, Tokyo, Japan, 1358550
- Local Institution
-
Shibuya-ku, Tokyo, Japan, 1508935
- Local Institution
-
Shinjuku-Ku, Tokyo, Japan, 1608582
- Local Institution
-
Shinjuku-ku, Tokyo, Japan, 1628655
- Local Institution
-
Tachikawa-shi, Tokyo, Japan, 1900014
- Local Institution
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Newly diagnosed with symptomatic Multiple Myeloma (MM)
- Have not received any prior systemic anti-myeloma therapy
- Have measurable disease
- Are not candidates for high-dose therapy plus stem-cell transplantation (SCT) because of age (≥ 65 years) or coexisting conditions. Refusal to undergo high dose therapy with SCT is NOT sufficient for entry onto CA204-116 for a subject < 65 years old. There must be a comorbidity that prevents SCT for a subject < 65 years old
Exclusion Criteria:
- Non-secretory myeloma
- Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Active plasma cell leukemia
- Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Arm A: Lenalidomide + Dexamethasone + Elotuzumab (BMS-901608)
Drug: Lenalidomide Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug Drug: Dexamethasone Tablets, Oral 28 mg and Intravenous (IV) 8 mg, once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug Tablets, Oral, 40 mg, once daily, on Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug Biological: Elotuzumab (BMS-901608) Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug |
|
Aktiv komparator: Arm B: Lenalidomide + Dexamethasone
Drug: Lenalidomide Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug Drug: Dexamethasone Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Objective Response Rate (ORR) of Participants Treated With Elotuzumab + Lenalidomide/Dexamethasone (E-Ld)
Tidsram: From first dose until documented response (assessed up to February 2017, approximately 24 months)
|
ORR is the proportion of randomized participants who achieve a stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or PR as determined by investigator using the International Myeloma Working Group (IMWG) response criteria. SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required. |
From first dose until documented response (assessed up to February 2017, approximately 24 months)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Objective Response Rate (ORR)
Tidsram: From first dose until documented response, up to approximately 72 months
|
ORR is the percentage of randomized participants who achieve a stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) as determined by investigator using the International Myeloma Working Group (IMWG) response criteria. SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required. |
From first dose until documented response, up to approximately 72 months
|
Progression Free Survival (PFS)
Tidsram: From randomization to the date of first documented tumor progression or death due to any cause, up to approximately 72 months
|
PFS is defined as the time from randomization to the date of the first documented tumor progression, as determined by the investigator using the International Myeloma Working Group (IMWG) response criteria, or to death due to any cause, provided death does not occur more than 10 weeks (2 or more assessment visits) after the last tumor assessment.
Clinical deterioration will not be considered progression.
|
From randomization to the date of first documented tumor progression or death due to any cause, up to approximately 72 months
|
Progression Free Survival (PFS) Rate
Tidsram: From randomization up to the specified timepoints, up to 3 years
|
PFS rate is defined as the percentage of participants who have neither progressed nor died at the specified timepoints
|
From randomization up to the specified timepoints, up to 3 years
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Hjärt-kärlsjukdomar
- Kärlsjukdomar
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer
- Lymfoproliferativa störningar
- Immunproliferativa störningar
- Hematologiska sjukdomar
- Hemorragiska störningar
- Hemostatiska störningar
- Paraproteinemier
- Blodproteinstörningar
- Multipelt myelom
- Neoplasmer, Plasmacell
- Läkemedels fysiologiska effekter
- Autonoma agenter
- Agenter från det perifera nervsystemet
- Antiinflammatoriska medel
- Antineoplastiska medel
- Immunologiska faktorer
- Antiemetika
- Gastrointestinala medel
- Glukokortikoider
- Hormoner
- Hormoner, hormonsubstitut och hormonantagonister
- Antineoplastiska medel, hormonella
- Angiogeneshämmare
- Angiogenesmodulerande medel
- Tillväxtämnen
- Tillväxthämmare
- Dexametason
- Lenalidomid
- Elotuzumab
Andra studie-ID-nummer
- CA204-116
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Multipelt myelom
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)AvslutadSteg I multipelt myelom | Steg II multipelt myelom | Steg III multipelt myelom | Refraktärt multipelt myelomFörenta staterna
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)AvslutadSteg I multipelt myelom | Steg II multipelt myelom | Steg III multipelt myelom | Refraktärt multipelt myelomFörenta staterna
-
Mayo ClinicAvslutadMultipelt myelom | Steg I multipelt myelom | Steg II multipelt myelom | Steg III multipelt myelom | Refraktärt multipelt myelomFörenta staterna
-
National Cancer Institute (NCI)AvslutadSteg I multipelt myelom | Steg II multipelt myelom | Steg III multipelt myelom | Refraktärt multipelt myelomFörenta staterna
-
National Cancer Institute (NCI)AvslutadSteg I multipelt myelom | Steg II multipelt myelom | Steg III multipelt myelom | Refraktärt multipelt myelomFörenta staterna
-
City of Hope Medical CenterAvslutadSteg I multipelt myelom | Steg II multipelt myelom | Steg III multipelt myelom | Refraktärt multipelt myelomFörenta staterna
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University och andra samarbetspartnersAktiv, inte rekryterandeMultipelt myelom vid återfall | Multipelt myelom med misslyckad remission | Multipelt myelom stadium I | Multipelt myelomprogression | Multipelt myelom steg II | Multipelt myelom steg IIIKanada
-
City of Hope Medical CenterAvslutadSteg I multipelt myelom | Steg II multipelt myelom | Steg III multipelt myelom | Rykande multipelt myelom | Refraktärt multipelt myelomFörenta staterna
-
University of WashingtonNational Cancer Institute (NCI)AvslutadSteg I multipelt myelom | Steg II multipelt myelom | Steg III multipelt myelom | Refraktärt multipelt myelomFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AvslutadSteg I multipelt myelom | Steg II multipelt myelom | Steg III multipelt myelom | Refraktärt multipelt myelomFörenta staterna
Kliniska prövningar på Lenalidomid
-
Celgene CorporationICON Clinical ResearchAvslutadMyelodysplastiska syndromTyskland, Israel, Storbritannien, Spanien, Belgien, Italien, Frankrike, Nederländerna, Sverige
-
Sidney Kimmel Comprehensive Cancer Center at Johns...AvslutadMyelodysplastiskt syndromFörenta staterna
-
Grupo Español de Linfomas y Transplante Autólogo...Celgene Corporation; Dynamic Science S.L.; Thermo Fisher Scientific, IncAvslutad
-
Swiss Group for Clinical Cancer ResearchAvslutadLymfomSchweiz, Norge, Sverige
-
Groupe Francophone des MyelodysplasiesOkändMyelodysplastiska syndromFrankrike
-
Boston VA Research Institute, Inc.Celgene Corporation; Edward Hines Jr. VA Hospital; Michael E. DeBakey VA... och andra samarbetspartnersAvslutadMultipelt myelomFörenta staterna
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's... och andra samarbetspartnersAvslutadWaldenströms makroglobulinemiFörenta staterna
-
European Organisation for Research and Treatment...AvslutadLymfomÖsterrike, Belgien, Spanien, Frankrike, Storbritannien, Tyskland, Finland, Schweiz
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)AvslutadNjurcancerFörenta staterna